Table 3.
Clinical outcomes of asymptomatic and symptomatic patients by the time of hospital closure
| Total (N = 214) | Asymptomatic (N = 26) | Symptomatic (N = 188) | P‐value | |
|---|---|---|---|---|
| Hospital discharge | 161 (75%) | 20 (77%) | 141 (75%) | 0.83 |
| Transferred to another hospital | 53 (25%) | 6 (23%) | 47 (25%) | |
| Length of hospital stay (days) | 17 (13–21) | 13 (12–15) | 18 (14–22) | 0.001 |
| Virus clearance | ||||
| SARS‐CoV‐2 clearance | 180 (84%) | 20 (77%) | 160 (85%) | 0.28 |
| Time from FVS to virus clearance (days) a | 16 (10–20) | 10 (8–12) | 16 (12–21) | <0.001 |
| Symptom onset to virus clearance (days) | – | – | 26 (20–33) | – |
| IgG | ||||
| IgG seroconversion | 199 (93%) | 22 (85%) | 177 (94%) | 0.07 |
| Time from FVS to IgG seroconversion (days) | 14 (8–17) | 7 (5–8) | 14 (9–19) | <0.001 |
| Symptom onset to IgG seroconversion (days) | – | – | 24 (18–29) | – |
| IgM | ||||
| IgM seroconversion | 147 (69%) | 8 (31%) | 139 (74%) | <0.001 |
| Time from FVS to IgM seroconversion (days) | 14 (8–17) | 8 (7–9) | 14 (10–18) | 0.001 |
| Symptom onset to IgM seroconversion (days) | – | – | 23 (18–29) | – |
FVS: the first virus‐positive screening; IgG, immunoglobulin G; IgM, immunoglobulin M; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2.
a
Interquartile ranges of continuous variables are shown in the table.